BioStock: Deal gives Iconovo long-term revenue potential

In July, Iconovo announced it had signed a regional licensing agreement with BNC Korea for the development of two inhalation capsule formulations for ICOcap: the generic forms of Novartis’s Ultibro and Seebri. The territory covered by BNC Korea represents about 15 per cent of total sales of the two formulations, giving Iconovo a substantial business opportunity.

Read the full article at biostock.se:

https://www.biostock.se/en/deal_gives_iconovo_long-term_revenue_potential/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se